Rosalyn A. Juergens, Ph.D.
Affiliations: | 2012 | Johns Hopkins University, Baltimore, MD |
Area:
OncologyGoogle:
"Rosalyn Juergens"Parents
Sign in to add mentor| Richard Ambinder | grad student | 2012 | Johns Hopkins | |
| (Targeting epigenetic changes in non-small cell lung cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Esfahanian N, Chan SWS, Zhan LJ, et al. (2023) Presentation and outcomes of KRAS mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. Cancer Treatment and Research Communications. 37: 100774 |
| Anagnostou V, Ho C, Nicholas G, et al. (2023) ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29: 2559-2569 |
| Li Y, Juergens RA, Finley C, et al. (2023) Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Rupp M, Fanton-Aita F, Snow S, et al. (2023) Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology (Toronto, Ont.). 30: 6559-6574 |
| Cheema PK, Banerji SO, Blais N, et al. (2023) Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology (Toronto, Ont.). 30: 6473-6496 |
| Melosky BL, Leighl NB, Dawe D, et al. (2023) Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. Current Oncology (Toronto, Ont.). 30: 6289-6315 |
| Ezeife DA, Spackman E, Juergens RA, et al. (2022) The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14: 17588359221112696 |
| Febbraro M, Gheware A, Kennedy T, et al. (2022) Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 42: 1-7 |
| Cheema PK, Banerji SO, Blais N, et al. (2021) Canadian Consensus Recommendations on the Management of -Altered NSCLC. Current Oncology (Toronto, Ont.). 28: 4552-4576 |
| Melosky B, Cheema P, Juergens RA, et al. (2021) The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13: 17588359211056306 |